Announcement on the Holding Subsidiary's Obtaining of the "Drug GMP Certificate"
Release time:
2020-08-05
Securities Code: 600668 Securities Short Name: Jianfeng Group Announcement No.: Pro 2018-026
Bond Short Name: 13 Jianfeng 02 Bond Code: 122344
Announcement of Zhejiang Jianfeng Group Co., Ltd.
on the acquisition of the "Drug GMP Certificate" by the holding subsidiary
The board of directors and all directors of the company guarantee this announcement There are no false records, misleading statements or major omissions, and they are individually and jointly liable for the authenticity, accuracy and completeness of their contents.
Recently, Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "the company") holding subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical") received Zhejiang Food The "Drug GMP Certificate" issued by the Drug Administration. The relevant information is hereby announced as follows:
1. GMP Certification Related Information
Enterprise Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Address: No.
Certificate No.: No. 368 Jinqu Road, Jinhua Industrial Park, Zhejiang Province: ZJ20180081
Certification Scope: Eye Drops, Ear Drops
Valid: august 2, 2023
2. involves production line capacity and main products:
Production Line Name |
Design Annual Capacity |
Variety |
Eye Drops Production Line |
Million |
Sodium Hyaluronate Eye Drops |
Ear Drops Production Line |
.5 Million |
Ofloxacin Ear Drops |
Market Situation of Main Products of 3. Company
Drug Name |
Dosage Form |
functional indications |
main manufacturer |
sodium hyaluronate eye drops |
eye drops |
are used for Sjogren's syndrome, Sjogren's syndrome, xerophthalmia |
towering pharmaceutical (China) co., ltd ; Qilu Pharmaceutical Co., Ltd.; Zhuhai Federal Pharmaceutical Co., Ltd. Zhongshan Branch; |
Ofloxacin Ear Drops |
Ear Drops |
is used to treat otitis media, otitis externa and tympanitis caused by sensitive bacteria |
Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd; Nanjing Tianlang Pharmaceutical Co., Ltd.; Wuhan Wujing Pharmaceutical Co., Ltd.; |
Note: 1. The information of "Main Manufacturers" in the fourth column of the table mainly comes from the website of china food and drug administration.
2, 2017, peak pharmaceutical sodium hyaluronate eye drops sales revenue of 15.9176 million yuan, the sales revenue of ofloxacin ear drops was 1.2665 million yuan.
Impact of 4. on Listed Companies and Risk Tips
The "Drug GMP Certificate" obtained by Jianfeng Pharmaceutical this time is not the certification certificate of the new production line, but the certificate obtained after the GMP certificate of its original eye drop and ear drop production line expires and is re-certified. Obtaining the GMP certificate again will help ensure the product quality and production capacity of Jianfeng Pharmaceutical, ensure market supply, and will not have a significant impact on the company's current operations. The specific future sales of various drugs of
Company may be affected by market environment, industry policy, supply and demand relationship and other factors, with uncertainty. Please the majority of investors cautious decision-making, pay attention to prevent investment risk.
is hereby announced.
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
August 14, 2018
More information
On the afternoon of June 9, Peak Cable Company organized all employees to learn fire fighting knowledge and conducted fire fighting and emergency escape drills. Since June, the subordinate enterprises of the company have organized training, learning and drills related to production safety according to their own characteristics and combined with the actual work. Safety production month series of activities carried out in an orderly manner.
2022
06-13
Spike Postdoctoral Research Papers on International Frontier Journals
Recently, good news came from the postdoctoral workstation of Jianfeng Pharmaceutical. Under the guidance of workstation mentor Jiang Xiaomeng, associate researcher Yang Xiaoxiao has made new progress in the treatment of alcoholic liver disease. The relevant research results "Roxadustat, a hypoxia-inducible factor 1a activator, attenuates both long- and short-term alcohol induced alcoholic liver disease" were published in the internationally renowned academic journal "Frontiers in Pharmacology. This journal is a frontier journal in the field of international pharmacy, mainly publishing academic papers and information on basic and clinical pharmacology, medicinal chemistry, pharmacology and toxicology.
2022
06-01
Daye Peak QC Achievements Won the Third Prize of Huangshi City
On May 7, Huangshi City Quality Strong City Working Committee organized a 2022 QC Results Conference. The QC project of "Technical Transformation of Ore Limestone Batching System" of Daye Peak Cement Company won the third prize.
2022
06-01
On April 28, Dalian Commodity Exchange held an online working meeting to announce the results of the 2021 excellent delivery warehouse and delivery warehouse excellent futures personnel selection, peak international trading company won the 2021 "excellent designated delivery warehouse" title, futures commissioner Ruan Weihang won the "excellent futures personnel" title.
2022
06-01
Cranberry extract combination identification detection method won the invention patent
After cranberry extract products were included in the "Zhejiang Province Key High-tech Product Development Project Plan" in 2021, Jianfeng Health Technology Company recently obtained an invention patent for the identification and detection method of cranberry extract. This new combined identification and detection method developed by Jianfeng Health identifies whether catechin or procyanidin B2 is added in cranberry extract by thin layer analysis, and then detects the unique A- type procyanidin and its chromatographic distribution in cranberry extract by high performance liquid chromatography, so as to improve the accuracy of product judgment. The identification method has the characteristics of accurate results and short detection time, which is of great significance to standardize the cranberry extract market and promote the healthy development of the industry, and has been unanimously recognized by peers.
2022
05-20
Daye Peak Manufacturing Department Won the Title of "Worker Pioneer" in Hubei Province
A few days ago, the manufacturing department of Daye Peak Cement Company was awarded the title of "Worker Pioneer" by the Hubei Provincial Federation of Trade Unions. Daye Jianfeng Manufacturing Department not only continued to actively explore and achieved good results in energy saving and consumption reduction, technological transformation, product quality process control, and economic responsibility system to guide management, but also improved Daye Jianfeng's overall operation level and won Huangshi City The seventh "Mayor Quality Award" created conditions and was fully affirmed by government departments at all levels.
2022
05-20
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page